Adc Therapeutics S.a.
Clinical trials sponsored by Adc Therapeutics S.a., explained in plain language.
A commercial-stage biotech company developing antibody-drug conjugates for cancer.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New cocktail of cancer drugs shows promise for tough lymphoma
Disease control OngoingThis early-stage study is testing a drug called loncastuximab tesirine (ZYNLONTA) combined with other anti-cancer agents in people whose B-cell non-Hodgkin lymphoma has come back or stopped responding to treatment. The main goal is to find safe doses and see how well the combinat…
Phase: PHASE1 • Sponsor: ADC Therapeutics S.A. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New hope for hard-to-treat lymphoma: drug duo takes on cancer
Disease control OngoingThis study tests whether a new drug combination (loncastuximab tesirine plus rituximab) works better than standard chemotherapy for adults with diffuse large B-cell lymphoma that has returned or not improved after initial treatment. About 440 participants will be randomly assigne…
Phase: PHASE3 • Sponsor: ADC Therapeutics S.A. • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC